AbCellera stock soars 35% on successful clinical trial result

AbCellera Biologics' clinical trial of ABCL635 demonstrated a significant reduction in moderate-to-severe menopausal hot flashes, achieving better results than placebo, which drove a 35% stock price surge. The treatment represents a potential best-in-class non-hormonal therapy with fewer health risks.

This Wire brief sits within Fusion42's coverage of Biotech.